Personalized Cell Therapy

Begins with You

Autologous iPSC-derived neuron replacement therapy for Parkinson’s disease

We are leveraging our in-house stem cell biology and genomics platform to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson’s disease.

Around 50% of dopamine neurons in the brain are lost before a Parkinson’s disease diagnosis. Even with the current standard of care therapy, patients can eventually develop debilitating motor complications. Our goal is to turn back the clock on Parkinson’s disease.

Technology Icon

Our Technology

Aspen Neuroscience is leading the science of using a patient’s own cells to develop personalized cell replacement therapies. This approach has the potential to restore lost function.

Our lead product ANPD001 has received IND clearance and Fast Track designation from the U.S. Food and Drug Administration, and is currently under investigation in the Phase 1/2a ASPIRO trial for the treatment of Parkinson’s disease.

Aspen’s autologous cell development platform starts with a small sample of the patient’s own skin cells, which are then reprogrammed to iPSCs unique to each patient, before differentiation into their final cell type for therapeutic delivery.

To treat greater numbers of patients with their own cells, Aspen Neuroscience is developing a robust, scalable, and automated biomanufacturing system at its new 22,000 square foot facility for GMP manufacturing of induced pluripotent stem cell (iPSC)-derived cell therapies. Aspen has entered into a collaboration and license agreement with Cell X Technologies for automating the iPSC stage of its autologous manufacturing platform.

Aspen Neuroscience has entered into a collaboration and license agreement with Cell X Technologies to advance Aspen’s plans for automating the iPSC stage of its autologous manufacturing platform.

Before being implanted, Aspen’s autologous cells are evaluated at every stage of the manufacturing process by Aspen’s proprietary genomics platform, which includes several machine learning based genetic tests to evaluate cell quality.

Commitment Patient Icon

Our Commitment to Patients

Patients helped found our company, are depending on us and are at the center of every decision we make.

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.